MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients\u2019 lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company\u2019s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time \/ 4:30 p.m. Eastern Time.<\/p>\n
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.<\/p>\n
About Sight Sciences<\/b>
\nSight Sciences is an eyecare technology company focused on developing and commercializing innovative and interventional solutions intended to transform care and improve patients\u2019 lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world\u2019s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company\u2019s OMNI\u00ae Surgical System is an implant-free glaucoma surgery technology (i) indicated in the United States to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and (ii) CE Marked for the catheterization and transluminal viscodilation of Schlemm\u2019s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma. Glaucoma is the world\u2019s leading cause of irreversible blindness. The SION\u00ae Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The Company\u2019s TearCare\u00ae System is 510(k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease (\u201cMGD\u201d), enabling clearance of gland obstructions by physicians to address the leading cause of dry eye disease. Visit www.sightsciences.com for more information. <\/p>\n
Sight Sciences, the Sight Sciences logo, TearCare, SmartHub and SmartLids are trademarks of Sight Sciences registered in the United States. OMNI and SION are trademarks of Sight Sciences registered in the United States, European Union and other territories.<\/p>\n
\u00a9 2025 Sight Sciences. All rights reserved.<\/p>\n
Media contact:<\/b>
\npr@sightsciences.com<\/p>\n
Investor contact:<\/b>
\nPhilip Taylor
\nGilmartin Group
\n415.937.5406
\ninvestor.relations@sightsciences.com<\/p>\n","protected":false},"excerpt":{"rendered":"
MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT) (\u201cSight Sciences\u201d or the \u201cCompany\u201d), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients\u2019 lives, today announced it will report financial results for the first quarter ended March 31, 2025, after […]<\/p>\n","protected":false},"author":2,"featured_media":1652,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[6],"tags":[],"class_list":["post-1676","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"\n